PuriCore Plc Result of General Meeting (8959L)
06 October 2016 - 9:43PM
UK Regulatory
TIDMPURI
RNS Number : 8959L
PuriCore Plc
06 October 2016
PuriCore plc
("PuriCore" or the "Company")
Result of General Meeting
6 October 2016 - PuriCore plc (AIM: PURI), the emerging
specialty biopharmaceutical company focused on leveraging its
proprietary immunomodulatory technology, announced on 20 September
2016 it had agreed to sell the Group's Supermarket Retail Business,
subject to Shareholder approval and other customary requirements,
to Chemstar Corp.
The Company is pleased to announce that the Resolution, as set
out in the notice of general meeting contained within the Circular
to Shareholders, approving the Disposal was duly passed at the
general meeting held today. Completion of the Disposal is expected
tomorrow and a further announcement will be made in due course.
Enquiries:
+44 (0) 20 3727
PuriCore plc 1000
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser and +44 (0) 20 7496
Broker) 3000
Aubrey Powell / Jen Boorer
This announcement contains inside information for the purposes
of Article 7 of Regulation 596/2014 (MAR).
Unless otherwise indicated, capitalised terms in this
announcement have the same definition as in the Circular.
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated a drug development programme, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes their formulations have novel immunomodulatory activity
with potential application for the treatment of diseases in a
number of therapeutic areas such as Dermatology, Ophthalmology and
potentially rare diseases. For more details, go to the Company's
website: www.puricore.com
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions shareholders and prospective shareholders not
to place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMDMMGGGVZGVZM
(END) Dow Jones Newswires
October 06, 2016 06:43 ET (10:43 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024